Lipoprotein(a) [Lp(a)] Test: Units, Risk, and Next Steps

A lipoprotein(a) result—usually written Lp(a) and pronounced “L-P little a”—measures a distinct ApoB-containing particle in blood. The concentration is mostly inherited and is associated with atherosclerotic cardiovascular disease and calcific aortic-valve stenosis. It is a risk marker, not a diagnosis, a personal forecast, or proof that Lp(a) caused a symptom or event.

The first task is identification, not conversion. Keep the exact value and its original mg/dL or nmol/L unit. Those units describe different properties of a structurally variable particle and cannot be translated with one reliable fixed multiplier.

What Lp(a) measures

Lp(a) is an LDL-like lipoprotein particle. It contains one apolipoprotein B-100 and an additional apolipoprotein(a), or apo(a), attached to it. That makes Lp(a) different from the cholesterol cargo reported as LDL-C and from total ApoB, which reflects the broader concentration of atherogenic ApoB-containing particles.

Epidemiologic and genetic evidence supports a continuous, likely causal relationship between higher Lp(a) concentration and higher risk of atherosclerotic cardiovascular disease and calcific aortic-valve stenosis. The 2022 European Atherosclerosis Society consensus statement also draws an important boundary: current findings do not support high Lp(a) as a risk factor for venous blood clots or impaired clot breakdown. Proposed mechanisms are not the same as a diagnosis in an individual.

Lp(a) belongs in an overall risk assessment—not in a one-number story about destiny, diagnosis, or treatment.

Mostly inherited does not mean perfectly fixed

Lp(a) concentration is predominantly determined by variation in the LPA gene. The 2026 ACC/AHA multisociety dyslipidemia guideline describes it as largely genetically determined and relatively stable over a lifetime. “Relatively stable” is more accurate than “fixed for life.”

Measurement can vary with the assay, and biological context can matter. Current European guidance notes that Lp(a) may rise after menopause and that a second measurement can be reasonable when a premenopausal result was borderline. A current clinical-laboratory review also identifies kidney, liver, thyroid, inflammatory, pregnancy, and menopause contexts that can affect a level. A timeline should preserve those facts rather than assign a cause.

Why current guidance says to measure it once in adulthood

The 2026 U.S. guideline recommends measuring Lp(a) at least once in all adults for atherosclerotic cardiovascular risk assessment. It also recommends cascade testing of first-degree relatives when a person has familial hypercholesterolemia, premature cardiovascular disease, or high Lp(a). The standard lipid panel does not automatically include Lp(a), so the source report should confirm that the test was actually performed.

This is population-level clinical guidance, not an instruction to order or repeat a test without a clinician. Repeat testing is generally unnecessary when a reliable result is clear and no relevant context has changed. A clinician may still consider another measurement when the first result is near a decision boundary, assay comparability is uncertain, or a health or life-stage change could affect interpretation.

mg/dL and nmol/L are separate measurement systems

Lp(a) can be reported as:

• mg/dL, a mass concentration; or
• nmol/L, a molar concentration that more directly represents the number of Lp(a) particles in a volume of blood.

The apo(a) protein varies substantially in size between people. That variation changes particle mass, so a fixed mass-to-molar conversion can overstate or understate the particle concentration. The American Heart Association scientific statement says there is no unbiased conversion factor between mg/dL and nmol/L. The current U.S. guideline prefers isoform-insensitive assays traceable to official reference materials and says the laboratory should report the assay and its calibrated unit.

Use only the matching lane:

• compare an mg/dL result with an mg/dL threshold;
• compare an nmol/L result with an nmol/L threshold; and
• if prior results use different units or laboratories, keep them separate unless the laboratory or clinician establishes comparability.

How current U.S. guidance frames a high result

The 2026 ACC/AHA guideline uses 125 nmol/L or higher and, in the separate mass lane, 50 mg/dL or higher as a risk-enhancing level. Its public summary associates either threshold with about a 1.4-fold increase in long-term heart attack or stroke risk. That is a relative population estimate, not a 40% absolute chance that an event will happen to an individual.

Risk rises across a continuum; it does not switch on at one line. The 2024 National Lipid Association focused update uses lower, intermediate, and higher risk bands and explicitly warns against fixed conversion. Age, blood pressure, diabetes, smoking, kidney health, existing cardiovascular disease, family history, LDL-C, non-HDL-C, ApoB, and other evidence shape absolute risk and the next clinical question.

The laboratory reference interval, a guideline risk-enhancing level, and a clinician-selected treatment goal are also different comparisons. Learn why in the guide to laboratory reference ranges.

What a high Lp(a) result does—and does not—change

The practical value of an elevated result is better risk classification. The current guideline emphasizes comprehensive cardiovascular risk assessment, healthful behaviors, and management of modifiable factors. Lifestyle measures usually have little direct effect on the inherited Lp(a) concentration, but they can still matter to overall cardiovascular health.

Treatment language needs another boundary:

• Statins are not Lp(a)-lowering drugs. Studies differ on whether Lp(a) stays unchanged or rises slightly, but that is not a reason to stop a statin prescribed to lower LDL-related risk.
• Some therapies can lower Lp(a) as a secondary effect. PCSK9 inhibitors and lipoprotein apheresis are used in defined clinical contexts; apheresis has a narrow U.S. indication for selected high-risk patients. Their mention here is not a recommendation or a treat-to-target plan.
• Targeted Lp(a)-lowering drugs are still being tested for outcomes. The registered phase 3 Lp(a)HORIZON trial is designed to test whether pelacarsen changes major cardiovascular events in people with established cardiovascular disease and elevated Lp(a). A lower laboratory number alone does not establish event benefit.

Do not start, stop, delay, or change a statin, aspirin, supplement, injectable, or other treatment from this article. A clinician can determine whether the Lp(a) result changes the intensity of an existing prevention plan.

A five-step way to prepare an Lp(a) result for review

1. Identify the exact result

Preserve lipoprotein(a) or Lp(a), the value, original unit, flag, source interval, specimen, laboratory, collection date, and report version. Do not confuse Lp(a) with LDL-C, an LDL particle test, ApoB, or apolipoprotein(a) isoform size.

2. Keep the unit unchanged

Label the result mg/dL or nmol/L exactly as reported. Compare it only with guidance expressed in that same unit. Never multiply or divide by a fixed factor to populate the other unit.

3. Capture assay and comparability details

Save the assay name, method, calibration, and comments when supplied. If they are absent, leave them unknown. The workflow for combining results from different laboratories can keep a comparison aligned, uncertain, or separate without inventing equivalence.

4. Attach the clinical context

Keep the reason for testing; personal and family cardiovascular history; related LDL-C, non-HDL-C, ApoB, blood pressure, and diabetes context; medicines; and relevant illness, kidney, liver, thyroid, pregnancy, or menopause context when applicable. Record facts without concluding that one caused the result.

5. Prepare bounded questions

Useful questions for the ordering clinician include:

• Which unit and assay produced this result, and is the measurement reliable enough for the intended decision?
• How does this value change my overall absolute-risk assessment?
• Should first-degree relatives discuss testing, given my result and family history?
• Is repeat testing useful here, or would it add little?
• Which modifiable risk factors and established goals apply to my situation?
• What follow-up fits the reason the test was ordered, and what changes should prompt earlier contact?

A bounded record-summary pattern

A source-aware note can say: “Lp(a) value, original unit, source interval, laboratory, assay or method if reported, collection date, report version, related lipid and risk context, family history, medicines, and reason for testing preserved; no unit conversion, diagnosis, causal event explanation, personal risk estimate, target, or treatment decision assigned.”

That is more useful than “high genetic cholesterol.” It keeps the evidence needed for review while leaving clinical interpretation with the qualified care team.

Where Libby fits

Libby can support the organization layer: keeping a supplied Lp(a) report, original unit, assay details, related lipid results, family context, medicines, and questions together. It does not convert Lp(a) units, establish assay comparability, calculate cardiovascular risk, diagnose plaque or valve disease, assess urgency, select a target, or recommend testing, treatment, or a dose.

If that source-linked record would help, you can start your record and use it to prepare the bounded questions above.

FAQ

What is lipoprotein(a), or Lp(a)? Lp(a) is an LDL-like particle with one ApoB-100 and an attached apolipoprotein(a). Its concentration is mostly inherited. Higher concentrations are associated with greater risk of atherosclerotic cardiovascular disease and calcific aortic-valve stenosis, but the result is not a diagnosis.

What Lp(a) level is considered high? The 2026 U.S. guideline uses 125 nmol/L or higher, or separately 50 mg/dL or higher, as a risk-enhancing level. Risk is continuous, and those lines do not set a universal diagnosis, personal probability, or treatment target.

Can I convert an Lp(a) result from mg/dL to nmol/L? Not with a reliable fixed factor. mg/dL measures mass; nmol/L is a molar concentration. Apo(a) size varies between people, so keep the original unit and use only guidance expressed in the same unit.

Does everyone need an Lp(a) test every year? No. The current U.S. guideline recommends at least one adult measurement for risk assessment, and repeat testing is generally unnecessary. A clinician may consider another result when the first is near a decision boundary, the assay is uncertain, or relevant clinical context changes.

Does high Lp(a) mean I have heart disease or aortic stenosis? No. It is a risk-enhancing factor, not proof of plaque, obstruction, valve disease, symptoms, or an impending event. Interpretation requires the rest of the cardiovascular and clinical context.

Can diet or exercise lower Lp(a)? Lifestyle usually has little direct effect on the predominantly inherited Lp(a) concentration. Healthful behaviors can still improve other cardiovascular risk factors, so “little effect on Lp(a)” does not mean they have no health value.

Do statins treat high Lp(a)? Statins are used to lower LDL-related cardiovascular risk, not to target Lp(a). Research reports unchanged or slightly higher Lp(a) with statins; that is not a reason to stop a prescribed statin. Medication decisions require a clinician's overall risk assessment.

Should my family members be tested if my Lp(a) is high? The 2026 guideline recommends cascade testing of first-degree relatives in families with high Lp(a), familial hypercholesterolemia, or premature cardiovascular disease. A clinician can apply age-appropriate guidance and the family's actual history rather than treating this article as a test order.

References

• 2026 ACC/AHA Multisociety Dyslipidemia Guideline — PubMed
• ACC/AHA Release: Updated Guideline for Managing Lipids and Cholesterol
• Focused Update on Lp(a) in Clinical Practice — National Lipid Association
• Lp(a) in ASCVD and Aortic Stenosis: European Atherosclerosis Society Consensus — PMC
• Lp(a): A Genetically Determined Cardiovascular Risk Factor: AHA Scientific Statement — PMC
• 2025 Focused Update of the ESC/EAS Dyslipidemia Guidelines — PubMed
• Fundamentals of Lp(a) Request and Quantification in the Clinical Laboratory — PMC
• About Lipoprotein(a) — CDC
• Lp(a)HORIZON Phase 3 Outcomes Trial — ClinicalTrials.gov

---

Educational content, not medical advice. Lp(a) interpretation depends on the reported unit, assay, source interval, collection and health context, family history, related cardiovascular evidence, and reason for testing. Discuss individual risk, repeat testing, family testing, treatment, and follow-up with the qualified clinician who knows why the test was ordered.